Monthly Archives: September 2013

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for September 10 2013

TradenameApplicantGeneric NamePatent Expiration
MYRBETRIQ
Apgdi
mirabegron
Sep 10, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Upcoming drug patent expirations by year

How Many Drug Patents Will Expire in the Coming Years?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for September 7 2013

TradenameApplicantGeneric NamePatent Expiration
SYMLIN
Amylin Pharms Llc
pramlintide acetate
Sep 7, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Top
selling drugs

What are the Top-selling Drugs?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for September 2 2013

TradenameApplicantGeneric NamePatent Expiration
LUPRON DEPOT
Abbott Endocrine
leuprolide acetate
Sep 2, 2013
LUPRON DEPOT
Abbvie Endocrine Inc
leuprolide acetate
Sep 2, 2013
LUPRON DEPOT-PED
Abbott Endocrine
leuprolide acetate
Sep 2, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharmaceutical companies recieved the most drug approvals last
year

Which Companies had the Most Drug Approvals Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Drug Patent Expirations for September 2013

Tradename Applicant Generic Name Patent Number Patent Expiration
LUPRON DEPOT Abbvie Endocrine Inc leuprolide acetate 5,575,987 Sep 2, 2013
LUPRON DEPOT-PED Abbott Endocrine leuprolide acetate 5,575,987 Sep 2, 2013
LUPRON DEPOT Abbott Endocrine leuprolide acetate 5,716,640 Sep 2, 2013
LUPRON DEPOT Abbvie Endocrine Inc leuprolide acetate 5,716,640 Sep 2, 2013
LUPRON DEPOT-PED Abbott Endocrine leuprolide acetate 5,716,640 Sep 2, 2013
LUPRON DEPOT Abbott Endocrine leuprolide acetate 5,575,987 Sep 2, 2013
SYMLIN Amylin Pharms Llc pramlintide acetate 6,608,029 Sep 7, 2013
OPANA ER Endo Pharms oxymorphone hydrochloride 5,662,933 Sep 9, 2013
OPANA ER Endo Pharms oxymorphone hydrochloride 5,958,456 Sep 9, 2013
MYRBETRIQ Apgdi mirabegron 6,699,503 Sep 10, 2013
PRELAY Sankyo troglitazone 6,046,202 Sep 15, 2013
CELLCEPT Roche Palo mycophenolate mofetil hydrochloride 5,543,408 Sep 15, 2013
REZULIN Pfizer Pharms troglitazone 5,602,133 Sep 15, 2013
CRINONE Watson Labs progesterone 5,543,150 Sep 15, 2013
PRELAY Sankyo troglitazone 5,602,133 Sep 15, 2013
REZULIN Pfizer Pharms troglitazone 6,046,202 Sep 15, 2013
CANCIDAS Merck caspofungin acetate 5,792,746*PED Sep 16, 2013
CANCIDAS Merck caspofungin acetate 5,378,804*PED Sep 16, 2013
AVODART Glaxosmithkline dutasteride 5,846,976 Sep 17, 2013
JALYN Glaxosmithkline dutasteride; tamsulosin hydrochloride 5,846,976 Sep 17, 2013
DIASTAT ACUDIAL Valeant diazepam 5,462,740 Sep 17, 2013
AVODART Glaxosmithkline dutasteride 5,998,427 Sep 17, 2013
JALYN Glaxosmithkline dutasteride; tamsulosin hydrochloride 5,998,427 Sep 17, 2013
DIASTAT Valeant diazepam 5,462,740 Sep 17, 2013
NIASPAN Abbvie niacin 6,406,715 Sep 20, 2013
ADVICOR Abbvie lovastatin; niacin 6,746,691 Sep 20, 2013
SIMCOR Abbvie niacin; simvastatin 6,676,967 Sep 20, 2013
NIASPAN Abbvie niacin 7,998,506 Sep 20, 2013
ADVICOR Abbvie lovastatin; niacin 6,818,229 Sep 20, 2013
SIMCOR Abbvie niacin; simvastatin 6,818,229 Sep 20, 2013
NIASPAN Abbvie niacin 6,746,691 Sep 20, 2013
SIMCOR Abbvie niacin; simvastatin 7,998,506 Sep 20, 2013
ADVICOR Abbvie lovastatin; niacin 6,406,715 Sep 20, 2013
NIASPAN TITRATION STARTER PACK Abbvie niacin 6,129,930 Sep 20, 2013
NIASPAN Abbvie niacin 6,676,967 Sep 20, 2013
SIMCOR Abbvie niacin; simvastatin 6,406,715 Sep 20, 2013
ADVICOR Abbvie lovastatin; niacin 7,998,506 Sep 20, 2013
NIASPAN TITRATION STARTER PACK Abbvie niacin 6,746,691 Sep 20, 2013
NIASPAN Abbvie niacin 7,011,848 Sep 20, 2013
ADVICOR Abbvie lovastatin; niacin 6,676,967 Sep 20, 2013
SIMCOR Abbvie niacin; simvastatin 6,746,691 Sep 20, 2013
NIASPAN Abbvie niacin 6,818,229 Sep 20, 2013
SIMCOR Abbvie niacin; simvastatin 7,011,848 Sep 20, 2013
ADVICOR Abbvie lovastatin; niacin 6,129,930 Sep 20, 2013
NIASPAN TITRATION STARTER PACK Abbvie niacin 7,011,848 Sep 20, 2013
NIASPAN Abbvie niacin 6,129,930 Sep 20, 2013
SIMCOR Abbvie niacin; simvastatin 6,129,930 Sep 20, 2013
ADVICOR Abbvie lovastatin; niacin 7,011,848 Sep 20, 2013
NIASPAN TITRATION STARTER PACK Abbvie niacin 6,406,715 Sep 20, 2013
ZYFLO CR Cornerstone Therap zileuton 6,183,778 Sep 21, 2013
NOVOLOG MIX 70/30 FLEXPEN Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,834,422 Sep 28, 2013
NOVOLOG MIX 50/50 Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,840,680 Sep 28, 2013
NOVOLOG MIX 70/30 PENFILL Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,834,422 Sep 28, 2013
NOVOLOG MIX 50/50 Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,834,422 Sep 28, 2013
ELIGARD Tolmar Therap leuprolide acetate 6,395,293 Sep 28, 2013
NOVOLOG MIX 70/30 PENFILL Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,547,930 Sep 28, 2013
NOVOLOG MIX 70/30 Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,840,680 Sep 28, 2013
NOVOLOG MIX 70/30 FLEXPEN Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,547,930 Sep 28, 2013
NOVOLOG MIX 70/30 FLEXPEN Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,840,680 Sep 28, 2013
NOVOLOG MIX 50/50 Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,547,930 Sep 28, 2013
NOVOLOG MIX 70/30 PENFILL Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,840,680 Sep 28, 2013
NOVOLOG MIX 70/30 Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,547,930 Sep 28, 2013
NOVOLOG MIX 70/30 Novo Nordisk Inc insulin aspart protamine recombinant; insulin aspart recombinant 5,834,422 Sep 28, 2013
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 5,911,851 Sep 29, 2013
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 6,503,362 Sep 29, 2013
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 6,007,676 Sep 29, 2013
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 5,472,143 Sep 29, 2013
LIDOSITE TOPICAL SYSTEM KIT Vyteris epinephrine; lidocaine hydrochloride 5,873,850 Sep 30, 2013
LEVULAN Dusa aminolevulinic acid hydrochloride 5,079,262 Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT Vyteris epinephrine; lidocaine hydrochloride 6,385,488 Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT Vyteris epinephrine; lidocaine hydrochloride 6,377,847 Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT Vyteris epinephrine; lidocaine hydrochloride 5,246,418 Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT Vyteris epinephrine; lidocaine hydrochloride 6,862,473 Sep 30, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for August 27 2013

TradenameApplicantGeneric Name Patent Expiration
CEREZYME
Genzyme
imiglucerase
Aug 27, 2013
ORFADIN
Swedish Orphan
nitisinone
Aug 27, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharmaceutical companies have the most drugs

Which Companies Have the Most Branded Drugs?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for August 22 2013

TradenameApplicantGeneric Name Patent Expiration
ISTODAX
Celgene
romidepsin
Aug 22, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Upcoming drug patent expirations by year

How Many Drug Patents Will Expire in the Coming Years?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for August 27 2013

TradenameApplicantGeneric Name Patent Expiration
CEREZYME
Genzyme
imiglucerase
Aug 27, 2013
ORFADIN
Swedish Orphan
nitisinone
Aug 27, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Upcoming drug patent expirations by year

How Many Drug Patents Will Expire in the Coming Years?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for August 20 2013

TradenameApplicantGeneric Name Patent Expiration
XOPENEX
Sunovion
levalbuterol hydrochloride
Aug 20, 2013
XOPENEX HFA
Sunovion
levalbuterol tartrate
Aug 20, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Upcoming drug patent expirations by year

How Many Drug Patents Will Expire in the Coming Years?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below.

For many, the PhD is not what it once was.

A problem academic institutions and industries are now facing is addressing the “massification” of PhD graduates; too many people are earning qualifications for roles that do not exist. A report from the Danish think tank DRUID reporting on post-doctorate career behaviour from a research orientated college found that job security is uncertain at best. Those who stay in the realm of academic/public research have their training valued and are promoted internally, but suffer from having a narrower scope of training for what has become a market of fixed term, non permanent positions.

These frustrations are echoed in the US. A 2007 Chronicle of Higher Education article notes this behaviour is beginning to drive people away from seeking positions in science. The Nature article “Indentured Labour” paints a poor picture: tenure-track positions remained at a constant level in the twenty years it took for the number of doctoral degrees awarded to double. People receiving their first National Institute of Health (NIH) grants are now in their early forties compared to those in their mid-30s being awarded grants in the 1970s. In short, the traditional academic career path is bottlenecking at an increasingly fast pace.

Anne Forde of Cambridge University’s careers service initially started out as a researcher in German Cancer Research Center before making the move to journalism, writing and later editing the Science Careers magazine. She says students are becoming increasingly aware of the realities of the modern job market.

“The research councils in the UK estimates that maybe only 1 in 10 PhDs students will end up in a long term 10 year academic post, so it’s not a minority issue to look at careers outside academia. So there is a lot of interest in looking at a broader career options because there are very few people who could say that they would be guaranteed a long term independent post in academia. We’ve always had a service for PhD students but there is an increasingly high demand for information and for guidance about careers outside the classic academic careers.”

“They probably aren’t aware of how complex the career choices or trajectories are or how much it isn’t a guarantee. And there’s a lot of mixed messages; the government is saying we need more scientist PhDs and we need more engineers for the economy, but the reality for somebody who is a PhD graduate is that the job market is still challenging. Unemployment rates for PhDs are in these cases low, but that doesn’t mean people are getting exactly the jobs they want at the right time and I think most students have to put in the effort to get the type of career they want. It’s difficult to get the message across that it’s not quite that straightforward; it is an area that needs, I think, addressing.”

The lateral move in life sciences is certainly not new, but signs of its encouragement are growing. A recent UK government report highlighted the “valley of death” phenomena that can occur between academia and industry; new applications have a more staggered path towards reaching industry due to the lack of expertise available for bridging such applications to market.

Perhaps this is down to the simple fact the passions and attitudes of researchers may simply not compel them to take up a business role. Deciding on such a drastic career change, where an entire new skill and knowledge set is required – alongside extra time commitments – can appear daunting to even the most experienced researcher. Fortunately, organisations such as ecosvc.com exist which go towards educating scientists to properly engage in turning their patents into financially sound business proposals. Even traditional research funding bodies are offering assistance to new companies, such as the NIH’s Commercialisation Assistance Program and the dedicated Biomedical Catalyst Scheme.

This movement between science and industry is a two way street. John Boyle left his managerial position in the pharmaceutical industry for what he terms as the “satisfying chaos” of academic research. Unlike researchers moving to business, immersing himself in “diverse, cutting-edge research problems” had tremendous appeal. Moving back to research also revealed to him surprising inefficiencies – seeing that people were expected to self-organise for research groups was “frustrating”, though his experience in management helped when given the responsibility for handling multiple, constantly changing projects. He also admits, however, that enforcing business-like process to the accepted research routine was met with more inefficiency and often hostility.

Finally, numerous examples exist of those whose experience initially lay in the ivory towers of business and academia going into other, tertiary science careers. As Anne Forde explains, the move into these initially unconventional fields has lost the negative stigma at the postgraduate level. “Traditionally they put a lot of their own funding into training PhDs and post-docs to be good at academic research. I think faced with the reality of how the academic job market is the majority of lecturers I have met do realise that many of their PhD students will have to look outside academia. They’re, in many cases, supportive of that and they try and help facilitate their student’s career transitions and often they have peers in other professions themselves.” This is once again reflected at an institutional level, with fellowships at the American Association for the Advancement of Science encouraging scientists who choose to go into science policy and communication and communication internship programs at the National Cancer Institute, to name but two.

About the author:

Fintan Burke is a student at the School of Biotechnology at Dublin City University. His main fields of interest include biomedical therapies and recombinant organisms.  Fintan may be contacted at fintan.burke2@mail.dcu.ie .